Individualised antibiotic treatment shortening therapy to median 3 days is safe and effective in culture-negative early-onset sepsis (EOS) among late-preterm and term neonates.
The approach significantly reduces antibiotic exposure compared to standard 5-7 days, potentially limiting antibiotic resistance and other adverse outcomes.
Non-inferiority was demonstrated for infection-related readmissions, supporting a clinically guided, biomarker-informed strategy.
The multicentre Danish DURATION trial provides robust evidence supporting antibiotic stewardship in neonatal EOS management.
